科倫藥業(002422.SZ):7個ADC項目授權默沙東合作事項通過反壟斷審查
格隆匯2月15日丨科倫藥業(002422.SZ)公吿稱,公司分別於2022年12月22日、2023年1月9日召開第七屆董事會第二十一次會議、2023年第一次臨時股東大會,審議通過了《關於控股子公司科倫博泰與默沙東簽署合作協議的議案》,同意公司控股子公司四川科倫博泰生物醫藥股份有限公司(簡稱“科倫博泰”)與MERCK SHARP & DOHME LLC.(簡稱“默沙東”)簽署《EXCLUSIVE LICENSEAND COLLABORATION AGREEMENT》(簡稱“《獨佔許可及合作協議》”),科倫博泰將其具有自主知識產權的7個ADC項目與默沙東開展合作。
截至美國東部時間2023年2月13日23時59分(北京時間2023年2月14日12時59分),默沙東與科倫博泰於2022年12月22日簽署的《獨佔許可及合作協議》中約定的通過HSR反壟斷審查的條件已滿足。前述反壟斷審查通過後,《獨佔許可及合作協議》中約定的協議生效條件已全部滿足,《獨佔許可及合作協議》已正式生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.